MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-14-2025
Precipio Interest Expense 2011-2025 | PRPO
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Precipio
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | -1 K | -14 K | - | 60 K | 11 K | 259 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 259 K | -14 K | 63 K |
Quarterly Interest Expense Precipio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -18 K | 898 K | - | - | -29 K | -11 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 268 K | -648 K | - | - | -2.65 M | -2.88 M | - | - | - | - | - | - | -6 K | - | -13 K | - | -1 K | - | - | - | 1 K | - | 53 K | - | -6 K | 8 K | 20 K | - | -2 K | 1 K | 231 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 898 K | -2.88 M | -252 K |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M |  USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 40.09 | -0.27 % | $ 1.11 B | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 21.26 | -2.34 % | $ 229 M |  China |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 10.04 | -0.99 % | $ 285 M |  Israel |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.52 | -0.65 % | $ 1.93 M | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 231.47 | 0.28 % | $ 169 B | USA |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.54 | -0.05 % | $ 18.8 B | USA |
 |
DexCom
DXCM
|
20.3 M | $ 67.42 | 0.84 % | $ 26 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 27.01 | -0.55 % | $ 817 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 19.73 | -1.45 % | $ 1.06 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 102.61 | 0.25 % | $ 4.05 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.42 | 3.64 % | $ 109 K | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 0.24 | -1.79 % | $ 7.04 M | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 226.02 | 0.39 % | $ 41 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Guardant Health
GH
|
-42.6 M | $ 102.38 | -0.12 % | $ 12.6 B | USA |
 |
NeoGenomics
NEO
|
-379 K | $ 12.3 | -0.97 % | $ 1.56 B | USA |
 |
Neogen Corporation
NEOG
|
38.1 M | $ 7.14 | -0.14 % | $ 1.55 B | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
National Research Corporation
NRC
|
862 K | $ 18.81 | -1.05 % | $ 462 M | USA |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.3 | -0.76 % | $ 902 M | USA |
 |
Organovo Holdings
ONVO
|
6 K | - | -2.3 % | $ 19.4 M | USA |
 |
OpGen
OPGN
|
7.56 K | - | -16.95 % | $ 1.54 M | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 417.16 | 0.18 % | $ 30.1 B |  Schweiz |
 |
Pacific Biosciences of California
PACB
|
14.3 M | $ 1.88 | 3.3 % | $ 477 M | USA |
 |
Illumina
ILMN
|
-292 M | $ 135.32 | -0.64 % | $ 21.5 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 203.16 | 0.14 % | $ 10.4 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 5.1 | - | $ 2.74 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 26.98 | 0.37 % | $ 20 B |  Niderland |
 |
PerkinElmer
PKI
|
-3.36 M | - | -0.91 % | $ 14.7 B | USA |
 |
Personalis
PSNL
|
24 K | $ 8.41 | -0.12 % | $ 498 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
30 M | $ 175.92 | 0.48 % | $ 19.5 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 6.82 | 1.04 % | $ 884 M | USA |